How to Get Vyleesi in Arkansas: Telehealth, Prescriptions, and Pharmacies

What Is Vyleesi and Why Does It Require a Prescription?

Bremelanotide is a melanocortin 3/4 receptor agonist administered as a self-injected 1.75 mg subcutaneous dose roughly 45 minutes before anticipated sexual activity. The FDA granted approval on June 21, 2019, based on the RECONNECT phase 3 trials, making it only the second FDA-approved pharmacotherapy for HSDD in premenopausal women. 1 Because the drug works centrally on hypothalamic melanocortin receptors, its safety profile including transient nausea and blood-pressure changes requires physician oversight. That oversight is precisely why a prescription is required, and why your prescriber needs a clinical picture before writing one.

The RECONNECT program enrolled 1,247 women across two replicate double-blind, placebo-controlled 24-week trials. 2 Bremelanotide produced a statistically significant improvement in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared with placebo (P<0.001). Those results anchored the FDA indication and continue to form the evidentiary basis that insurers, including Arkansas Medicaid, cite when evaluating prior-authorization requests. 2

Is Telehealth Legal for Vyleesi Prescriptions in Arkansas?

Arkansas permits telehealth prescribing for bremelanotide. Yes, a licensed clinician can evaluate you entirely online and send the prescription to an Arkansas-licensed pharmacy. Arkansas Code Annotated section 17-80-117 governs telemedicine practice, and the Arkansas State Medical Board has confirmed that a valid patient-physician relationship may be established via synchronous audio-video telehealth, which is the standard used by most HSDD-focused platforms. 3

The visit itself typically takes 20 to 30 minutes. Your clinician will review your sexual health history, screen for cardiovascular contraindications, confirm you are premenopausal, and administer a validated tool such as the Female Sexual Function Index (FSFI) or the FSDS-DAO. Studies using the FSFI confirm that a score below 26.55 correlates with female sexual dysfunction broadly. 4 That objective threshold gives the prescriber a documentable clinical finding, which matters if you later need to appeal a prior-authorization denial.

One practical note: use a platform that operates under Arkansas licensure specifically. Some national hormone-therapy telehealth services hold licenses in only certain states. Confirm Arkansas coverage before booking and ensure the prescribing clinician holds an active Arkansas DEA registration or, for non-controlled substances like bremelanotide, at minimum an active Arkansas medical or advanced-practice license.

What Labs or Workup Do You Need Before Getting Vyleesi?

Bremelanotide is not a hormone and does not require hormone panels. The standard pre-prescription workup is lighter than most people expect. Your clinician will typically want the following:

Blood pressure reading. Bremelanotide transiently raises systolic blood pressure by a mean of 6 mmHg and diastolic by 3 mmHg, peaking 12 minutes post-injection and resolving within 12 hours. 1 Women with uncontrolled hypertension or known cardiovascular disease are excluded per the FDA label.

Pregnancy status confirmation. The FDA label contraindicates bremelanotide in pregnancy. 1 A urine pregnancy test or recent negative test result satisfies this requirement in most telehealth workflows.

Medication reconciliation for naltrexone. Co-administration with naltrexone reduces naltrexone AUC by 35%, which is clinically significant if you take naltrexone for opioid use disorder or alcohol dependence. 1 Disclose all medications during your telehealth intake.

Menstrual or menopausal status documentation. The FDA approval covers premenopausal women only. Your clinician may ask your last menstrual period date or request FSH results if menopause status is unclear, particularly in women over 45.

No liver panel, lipid panel, or fasting glucose is required by the label. Many telehealth platforms complete the full intake using a digital questionnaire that patients fill out before the video visit, which shortens the actual appointment considerably.

Who Can Prescribe Vyleesi in Arkansas?

In Arkansas, the following clinician types may legally prescribe bremelanotide:

MDs and DOs hold full independent prescribing authority in Arkansas and may prescribe Vyleesi without restriction beyond their clinical scope.

Nurse Practitioners (NPs) in Arkansas operate under a reduced-practice environment. Under Arkansas law, NPs require a physician collaborative agreement to prescribe independently, although legislation passed in recent years has expanded practice authority in underserved areas. 5 An NP affiliated with a telehealth platform typically satisfies this through a physician-of-record arrangement built into the platform's structure.

Physician Assistants (PAs) must practice under physician supervision in Arkansas. A supervising physician must be identified on file, but the PA can conduct the telehealth visit and write the prescription within that supervisory framework.

OB-GYNs, sexual medicine specialists, and women's health-focused internists are the most common prescribers of bremelanotide nationally. A 2021 survey of sexual medicine practitioners found that HSDD is underdiagnosed partly because fewer than 30% of primary care physicians routinely screen for it using validated tools. 6 Telehealth platforms specializing in women's sexual health tend to have higher prescribing familiarity with Vyleesi than general primary care.

How Does Arkansas Medicaid Prior Authorization Work for Vyleesi?

Arkansas Medicaid covers bremelanotide under a limited prior-authorization pathway. The word "limited" means approval is possible but not automatic, and the documentation burden is meaningful.

A standard Arkansas Medicaid PA submission for Vyleesi typically requires:

1. Diagnosis code F52.0 (hypoactive sexual desire dysfunction) or F52.9 (unspecified sexual dysfunction) documented in the medical record.
2. Validated assessment score such as the FSDS-DAO or FSFI, with the score and date recorded in the clinical note.
3. Premenopausal status confirmation stated explicitly in the prescribing note.
4. Absence of contraindications including cardiovascular disease, uncontrolled hypertension, or concurrent naltrexone use.
5. Trial or consideration of first-line interventions, which Medicaid reviewers often interpret as documentation that psychotherapy, relationship counseling, or hormone evaluation was considered or attempted.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states that "the diagnosis of HSDD requires both low desire and associated personal distress," and that pharmacotherapy is appropriate when non-pharmacologic approaches have not adequately addressed patient distress. 7 Including that language in the clinical note directly maps to the ACOG standard and may reduce PA denial rates.

If Arkansas Medicaid denies the initial request, you have the right to appeal. The administrative denial typically comes with an explanation of the specific criterion not met, which gives you a targeted basis for the appeal letter. Most successful appeals add one additional piece of documentation such as a psychotherapy referral note or a repeat validated symptom score.

For patients with commercial insurance, coverage varies by plan. Most commercial plans in Arkansas treat Vyleesi as a specialty pharmaceutical with a step-edit or PA requirement similar in structure to the Medicaid pathway. Out-of-pocket cost without insurance runs approximately $800 to $1,000 per month at retail pharmacies. Palatin Technologies has offered a savings card that can bring the cost to around $99 per fill for eligible commercially insured patients. Confirm current eligibility at the manufacturer's website before your appointment.

Can You Get Bremelanotide from a 503A Compounding Pharmacy in Arkansas?

Licensed 503A compounding pharmacies in Arkansas may compound bremelanotide for individual patients. 503A pharmacies compound on a patient-specific, prescription-by-prescription basis under state pharmacy board oversight and federal FDCA section 503A. 8 The compounded form is not FDA-approved the way the branded Vyleesi auto-injector is, and the FDA has not placed bremelanotide on its list of drugs withdrawn from market for safety reasons, which is a prerequisite for 503A eligibility.

Why would a patient choose compounded bremelanotide over branded Vyleesi? Cost is the primary driver. Compounded bremelanotide peptide vials from a 503A pharmacy can cost 60% to 80% less than brand-name Vyleesi at retail, which matters substantially when insurance denies coverage. The tradeoff is that compounded products lack the FDA-reviewed manufacturing controls applied to the branded auto-injector, and dosing precision depends on the pharmacy's quality systems.

To use a 503A compounding pharmacy in Arkansas, your prescriber must write the prescription specifying the compounded form, concentration, and vehicle. The prescription is then sent directly to the compounding pharmacy, which ships to your Arkansas address. Confirm that the pharmacy holds an active Arkansas State Board of Pharmacy license before transferring any prescription. The Arkansas State Board of Pharmacy maintains a publicly searchable licensee database at pharmacy.arkansas.gov.

How Long Does It Take to Receive Vyleesi in Arkansas?

From completed telehealth visit to medication-in-hand, the timeline breaks down as follows:

Same day to 24 hours: The prescriber sends the prescription electronically to the pharmacy. For telehealth platforms with integrated pharmacy networks, this step is often automated at visit completion.

1 to 3 business days: Commercial pharmacies process the prescription, which for specialty medications often includes an insurance verification or PA initiation step. If no prior authorization is needed, branded Vyleesi can ship same day from a specialty pharmacy.

3 to 5 business days: Standard USPS Priority or FedEx ground shipping to most Arkansas zip codes. Specialty pharmacies serving Arkansas include those licensed in Arkansas and shipping cold-chain medications to all 75 counties.

Up to 14 business days if PA is required. Arkansas Medicaid standard PA decisions are issued within 14 calendar days under normal review timelines. Urgent PA decisions may be issued within 72 hours if the prescriber documents clinical urgency.

Total realistic timeline for a patient with commercial insurance requiring prior authorization: 7 to 14 business days. A patient paying cash through a telehealth platform with an in-network 503A pharmacy may receive medication in 3 to 5 business days.

How to Use Vyleesi Once You Have It

The auto-injector contains a single 1.75 mg dose. You inject subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. The FDA label recommends against using more than one dose within 24 hours. 1

Nausea is the most common adverse effect, reported by 40% of participants in RECONNECT. 2 Taking an over-the-counter antiemetic such as ondansetron 4 mg or promethazine 25 mg 30 minutes before the injection may reduce nausea severity. Your prescriber can advise on antiemetic choice based on your medication list. Flushing occurred in 20% of RECONNECT participants, and hyperpigmentation of the face, gums, or breasts was reported with chronic use; the label accordingly recommends using Vyleesi no more frequently than once per 24 hours. 1

Store auto-injectors at room temperature up to 77 degrees Fahrenheit. Do not refrigerate or freeze the auto-injector, as temperature extremes affect the formulation. Compounded vials from 503A pharmacies may have different storage requirements; follow the pharmacy's specific instructions for the formulation dispensed.

Comparing Bremelanotide to Flibanserin (Addyi) for Arkansas Patients

Flibanserin (Addyi) is the other FDA-approved HSDD pharmacotherapy. It is a daily oral 100 mg tablet taken at bedtime, approved in 2015. 9 Vyleesi is an as-needed subcutaneous injection. The choice between them depends on patient preference and contraindication profile.

Flibanserin carries a black-box warning against alcohol consumption and against use with moderate or strong CYP3A4 inhibitors, including many common antibiotics and antifungals. 9 Bremelanotide has no alcohol interaction restriction, which many patients find practically important. A 2020 review in the Journal of Sexual Medicine compared the two agents and found that patient-reported treatment preference data favored the as-needed dosing model of bremelanotide for women who found daily pill adherence burdensome. 10 Neither agent outperforms the other on efficacy; the RECONNECT and DAISY/VIOLET flibanserin trials both showed modest but statistically significant improvements over placebo, and both agents are considered appropriate first-line pharmacotherapy for HSDD by sexual medicine specialists.

Arkansas Medicaid covers flibanserin under a similar limited PA pathway. If one agent is denied, prescribers sometimes submit the alternative with documentation of the denial, which can support the medical necessity argument for the second agent.

Transferring an Existing Vyleesi Prescription to Arkansas

If you hold an active Vyleesi prescription from another state and have moved to Arkansas, transferring it is straightforward for commercial prescriptions. Under Arkansas pharmacy law, a pharmacy licensed in Arkansas may accept a transferred prescription from an out-of-state pharmacy, provided the original prescription has remaining refills and was written by a licensed prescriber. The receiving Arkansas pharmacy will contact the originating pharmacy to confirm the transfer.

Arkansas Medicaid is state-specific: a prescription previously covered under another state's Medicaid does not automatically transfer coverage. You will need to re-enroll in Arkansas Medicaid, submit a new PA request, and have a new prescription written by an Arkansas-licensed provider. A telehealth clinician licensed in Arkansas can handle this re-initiation visit entirely online, which avoids the need to find a new in-person provider during a relocation period.

For 503A compounded bremelanotide, the original prescription generally cannot be transferred to a new pharmacy under federal compounding rules; a new prescription from an Arkansas-licensed provider is typically required. Most telehealth platforms can generate a new prescription at a follow-up visit within 24 to 48 hours of request.

Practical Step-by-Step: Getting Vyleesi in Arkansas

1. Book a telehealth visit with a platform that holds Arkansas licensure and has clinicians experienced in women's sexual health.
2. Complete the digital intake questionnaire covering sexual health history, cardiovascular risk factors, current medications, and menstrual status.
3. Attend the video visit. The clinician will administer a validated HSDD screening tool and confirm the FSDS-DAO or FSFI score in the clinical note.
4. If you have Arkansas Medicaid or commercial insurance, ask the prescriber to initiate the PA at the time of the visit. Many telehealth platforms have in-house PA specialists who handle submission.
5. Choose your pharmacy: a retail pharmacy that stocks branded Vyleesi, a specialty pharmacy with shipping capability, or an Arkansas-licensed 503A compounding pharmacy if cost is a barrier.
6. Receive the auto-injector or compounded vial. Review the injection technique with your pharmacist or via the manufacturer's instructional materials before first use.
7. Follow up with your prescriber at 4 to 8 weeks to assess response using the same validated tool administered at baseline.

The RECONNECT trial measured primary endpoints at 24 weeks. 2 If you have not seen meaningful improvement in desire-related distress by 8 to 12 weeks of consistent use, your clinician may consider whether dose timing adjustments, antiemetic pre-treatment, or an alternative therapeutic approach is warranted. Contact your prescriber before discontinuing, since some patients report gradual response improvement over the first 3 months of use.